Dahms Bradford D.
- SEC CIK
- 0001787307
No open-market purchases or sales filed in the past year.
Current role at each company
- JBIO Jade Biosciences, Inc.Chief Financial Officeras of Feb 13, 2026
- THRX Theseus Pharmaceuticals, Inc.President and CFOas of Feb 14, 2024
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Dahms Bradford D. as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
THRX Theseus Pharmaceuticals, Inc.
President and CFO2 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 1, 2022 (view filing) | Nov 30 | 1 day | Dahms Bradford D.Chief Financial Officer | PPurchase | +1.50K | $6.66 | +$10.0K | +32.4%6.14K after | |
| Dec 22, 2021 (view filing) | Dec 21 | 1 day | Dahms Bradford D.Chief Financial Officer | PPurchase | +1.97K | $10.15 | +$20.0K | New position1.97K after |